An observational study in Carcinoma, Hepatocellular, Hepatocellular Cancer and Liver Cancer, sponsored by Eastern Hepatobiliary Surgery Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Eastern Hepatobiliary Surgery Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Carcinoma, Hepatocellular by Eastern Hepatobiliary Surgery Hospital — 6 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Hepatocellular · Eastern Hepatobiliary Surgery Hospital.
Among the 51 studies in Carcinoma, Hepatocellular by Eastern Hepatobiliary Surgery Hospital, this one is the only one that started in 2022, is one of 7 observational ones, and was the 44th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →6 of the 51 studies in Carcinoma, Hepatocellular by Eastern Hepatobiliary Surgery Hospital are open now, in 1 country. Recruiting first, the newest first:
Eastern Hepatobiliary Surgery Hospital · Sites in China
Ages 18+ · Healthy volunteers
Eastern Hepatobiliary Surgery Hospital · Sites in China
Ages 18–75
Eastern Hepatobiliary Surgery Hospital
Ages 18–80 · Healthy volunteers
Eastern Hepatobiliary Surgery Hospital
Ages 18–70
Eastern Hepatobiliary Surgery Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 4 · Phase 4 2
First in 2008; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,650 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 170 across the 44 interventional studies, 1,000 across the 7 observational. Of the 32 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eastern Hepatobiliary Surgery Hospital is the lead sponsor of 69 studies on the registry; 13 are open to participants now.
1 of the studies in Carcinoma, Hepatocellular by Eastern Hepatobiliary Surgery Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07707661Eastern Hepatobiliary Surgery HospitalApplication of Super-Resolution Ultrasound (SRUS) in Liver Tumor | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies in Carcinoma, Hepatocellular by Eastern Hepatobiliary Surgery Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Effective strategies for personalized treatment decisions for early-stage hepatocellular carcinoma (HCC) remain critically limited. Microvascular invasion (MVI) is a distinctive pathological hallmark of HCC invasiveness. Current evidence underscores that accurate preoperative prediction of MVI has the potential to support personalized selection among surgical resection, liver transplantation, and local ablation, as well as different approaches within each modality. However, despite numerous studies on MVI prediction, accuracy remains insufficient. Currently, radiomics and liquid biopsy are at the forefront of MVI prediction. Furthermore, combining both technologies may offer a more reliable prediction, but this integrated approach remains unexplored.
This large-scale prospective cohort study (an observational study design). aims to develop a multimodal approach to predict MVI by integrating four data sources: clinicopathological variables, MRI-based radiomics features, MRI-based deep learning features, and MVI-related genomic alterations detected in circulating cell-free DNA (cfDNA). Individual models will first be developed for each data modality. Their predictive outputs will be calibrated into standardized risk probabilities and integrated via decision-level fusion to generate the final multimodal model. This system will be used to preoperatively stratify patients by predicted MVI risks.
Based on this risk stratification, a re-staging system for early-stage HCC will be developed. Its prognostic value and clinical utility will be evaluated, with its ability to guide the selection of optimal resection margins to improve outcomes as a key illustrative example.
The primary endpoints are 5-year recurrence-free survival (RFS), 5-year overall survival (OS), and recurrence patterns.
1. Study rationale and scope
MVI predictiion has the potential to guide individualized treatment decisions. Microvascular invasion (MVI), a hallmark of HCC invasiveness, is present in 20.0% to 45.9% of resected early-stage HCC specimens and strongly indicates a high recurrence risk and the need for adjuvant therapy. Current studies have highlighted the critical and potential value of preoperative MVI status to guide initial treatment selection. In brief, for patients with MVI, more aggressive treatments may effectively reduce recurrence, while for those without MVI, less aggressive therapies can ensure outcomes while being safer and more cost-effective. These findings underscore the critical role of MVI in guiding treatment selection.
However, since MVI can only be diagnosed through postoperative histopathology, its presence or absence preoperatively requires prediction. Moreover, current studies suggest that preoperative MVI prediction has the potential to guide not only the choice among resection, transplantation, and ablation but also specific technical decisions, such as resection type, resection or ablation margin width, and the use of neoadjuvant therapy. It also prompts a reconsideration of current transplantation criteria.
Numerous studies have utilized clinical characteristics, tumor features from imaging studies, laboratory tests including tumor markers (e.g., α-fetoprotein [AFP], α-fetoprotein lens culinaris agglutinin-reactive fraction 3 [AFP-L3], prothrombin induced by vitamin K absence-II [PIVKA-II]), and multifactorial clinical models for MVI prediction. However, the sensitivity and specificity of these methods remain insufficient, limiting their widespread clinical application.
Radiomics, which encompasses techniques utilizing contrast-enhanced CT, MRI, ultrasound, and PET-CT, has demonstrated superior performance, with MRI-based radiomics being particularly notable. This advantage derives from MRI's excellent soft-tissue contrast and multiparametric imaging capabilities. These capabilities are further enhanced by machine learning (ML) and deep learning (DL) technologies, which capture more subtle tumor features, thereby improving the sensitivity and robustness of predictions. However, despite numerous successful reports, the clinical translation of radiomics faces challenges. Beyond technical factors, which are expected to be overcome with technological advancements, a limitation in tumor biology exists: radiomics-based prediction can be suboptimal when aggressive tumor biology has not yet manifested as discernible changes on imaging-a key limitation in predicting MVI for early-stage HCC.
Certain genomic alterations detected in HCC tumor tissues have the potential to predict MVI. However, current guidelines do not recommend preoperative biopsy for resectable HCC due to the risk of tumor needle tract dissemination. Additionally, intratumoral heterogeneity significantly affects testing accuracy.
Liquid biopsy, with its ability to detect minimal residual disease (MRD), may enable accurate MVI prediction. However, the application of current liquid biopsy methods is limited by low sensitivity, technical complexity, and an inability to fully characterize tumor heterogeneity. Circulating cell-free DNA (cfDNA) containing cancer-specific information can more accurately characterize tumor-invasive capability. Thus, cfDNA testing represents a novel approach with the potential to accurately estimate MVI risk, although supporting data remain scarce.
Furthermore, combining cfDNA analysis with radiomics may complementarily capture both the biological behavior and structural features of MVI, thereby improving predictive performance. However, this integrated approach remains unexplored.
(4) The strategy of predicting MVI to guide treatment decisions is only applicable to very early and early-stage HCC (BCLC stage 0 or A).
The treatment strategies for intermediate- and advanced-stage HCC differ from those for early-stage HCC, and the biomarkers guiding treatment decisions for these stages are different from or not limited to MVI.
2. Study design
This study has been approved by the Institutional Ethics Committee of each center, and informed consents have been obtained from all patients for their tissues or blood samples and clinical data to be used for research purposes.
3. Patients and enrollment
(1) Inclusion criteria
1) Age between 18 and 75 years; 2) Histopathologically confirmed HCC; 3) Very early and early-stage HCC meeting BCLC stage 0 or A; 4) Child-Pugh class A or B liver function; 5) Undergoing curative-intent resection, defined as complete tumor removal with tumor-free resection margins, without major vascular invasion or extrahepatic distant metastasis; 6) No preoperative anti-cancer treatment prior to surgery; 7) Availability of preoperative contrast-enhanced MRI data eligible for imaging tumor feature assessment; 8) Availability of preoperative peripheral blood sample for cfDNA sequencing (only for patients with cfDNA seq mutation analysis); 9) Availability of complete clinicopathological and follow-up data; 10) Written informed consent for research use of clinicopathological data and biological samples.
(2) Exclusion criteria
We have also established a prospective cohort of 650 patients from four Chinese tertiary medical centers: Zhongda Hospital (Southeast University), Mengchao Hepatobiliary Hospital (Fujian Medical University), Sun Yat-Sen Memorial Hospital (Sun Yat-Sen University), and Eastern Hepatobiliary Surgery Hospital (EHBH). These patients had undergone HCC resection between January 2016 and June 2019. The paired tumor/non-tumor tissue or cell-free DNA (cfDNA) sequencing data of these patients are available. Tumor tissue sequencing data are analyzed to identify MVI-related mutations for the development of a targeted cfDNA sequencing panel. The MVI-related genomic signatures detected in cfDNA sequencing are then used to develop a cfDNA-based MVI-predictive model.
For all enrolled patients, their clinicopathological variables will be utilized to develop the clinical MVI-predictive model.
4. Patient grouping
(1) Step 1: Grouping for developing four individual MVI-predictive models.
The final multimodal fusion model will be developed by integrating the predictions from the four individual models.
(2) Step 2: Grouping (re-staging) of early-stage HCC into MVI high-risk and low-risk groups (substages) based on the multimodal MVI prediction.
This analysis will be conducted within the cfDNA cohort, as patients in this group possess all data types required for multimodal MVI prediction, including clinicopathological variables, contrast-enhanced MRI findings, and cfDNA sequencing data.
Based on the risk stratification determined by the multimodal MVI prediction model, patients with early-stage HCC will be re-staged into two substages: the MVI high-risk and MVI low-risk groups. The 5-year OS, 5-year RFS, and recurrence patterns will be compared between the two groups to evaluate the prognostic accuracy of this re-staging system.
(3) Step 3: Grouping for validating the accuracy of re-staging in guiding clinical decisions.
Following the analysis in Step 2, we will evaluate the clinical utility of the re-staging system for surgical decision-making, using the selection of optimal resection margin width as an illustrative example. The MVI high-risk group will be divided into two subgroups: wide-margin resection and narrow-margin resection. The 5-year OS, 5-year RFS, and recurrence patterns will be compared between the two subgroups. The same analysis will be conducted in the MVI low-risk group.
The results will indicate whether the re-staging system can accurately guide the individualized selection of resection margin width in early-stage HCC.
5. Clinical management and follow-up
6. Development of clinical MVI-predictive model Preoperative clinical variables include age, sex, total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, platelets, prothrombin time (PT), AFP, PIVKA-II, hepatitis B and C serology, HBV-DNA levels, and imaging features such as tumor number, tumor diameter and cirrhosis on preoperative contrast-enhanced MRI.
The clinical model is developed using clinicopathological variables selected based on univariate logistic regression analysis, retaining only those with a P value \<0.05. These statistically significant variables are then used as input features to train an XGBoost model. This model is built by iteratively adding decision trees, each designed to correct the errors of previous trees, with hyperparameters such as learning rate, tree depth, and subsample ratio optimized via cross-validation. The final model outputs a continuous risk score (or a calibrated probability) for predicting MVI, capturing non-linear relationships and complex interactions among clinical variables that cannot be readily modeled by logistic regression. Alternatively, feature selection can be refined using XGBoost's built-in gain-based importance scores after an initial univariate filter.
7. Development of MRI-based radiomics and deep learning MVI-predictive models
8. Development of cfDNA genomic signature-based MVI-predictive model
To build the predictive model, background noise introduced by random NGS errors is first removed from cfDNA and WBC data using an AccuraGen proprietary algorithm. Somatic mutations in cfDNA are identified by cross-referencing tumor-tissue mutations with germline variants from WBCs; the maxAF of each somatically mutated gene is used as a quantitative somatic signature. Germline SNPs and indels detected in WBCs are recorded as binary (presence/absence) germline signatures. Significant signatures are selected through univariable logistic regression followed by forward stepwise multivariable selection, optimized for maximum area under the receiver operating characteristic curve (AUC). These selected somatic and germline signatures are finally integrated into a cfDNA-based model to predict MVI status. Candidate algorithms, including XGBoost, penalized logistic regression and gradient-boosted decision trees (GBDT), will be evaluated within the training data using nested cross-validation, and the final algorithm will be selected according to prespecified performance.
9. Development of multimodal MVI-predictive model As noted earlier, four individual models are developed to preoperatively assess MVI risk: a clinical model, an MRI-based radiomics model, an MRI-based deep learning image model, and a cfDNA mutation model. To enable standardized integration across heterogeneous data modalities, raw outputs from the four individual models are calibrated into risk probabilities ranging from 0.0 to 1.0 using Platt scaling or isotonic regression. Platt scaling fits a logistic regression model to the raw scores, assuming a sigmoidal relationship, and is particularly effective when the uncalibrated outputs are from support vector machines or similarly distributed models. In contrast, isotonic regression learns a nonparametric, piecewise-constant monotonic function from the data, making no prior assumption about the shape of the calibration curve but requiring a larger calibration set to avoid overfitting. This calibration step ensures that scores from different sources are comparable and well-suited for downstream combination, especially when model outputs are not naturally probabilistic. The calibrated probabilities will be clipped to avoid boundary values of 0 and 1 and transformed to logits before being entered into an L2-regularized logistic stacking model. The fusion coefficients of the final multimodal system will be estimated exclusively from out-of-fold predictions. After all preprocessing, calibration, fusion and threshold-selection procedures have been locked, the complete pipeline will be refitted using the full training cohort and evaluated once in the temporally independent validation cohort, which will remain inaccessible throughout model development. .
10. Development of re-staging system for early-stage HCC The total risk probability of MVI prediction of each patient is calculated, and ROC analysis is used to calculate the optimal cutoff value of the multimodal model to distinguish between high and low-risk for MVI by maximizing the Youden index (i.e., sensitivity+specificity-1). Using this cutoff value, patients with early-stage HCC with a predicted MVI probability at or above the cutoff determined by the maximum Youden index will be classified as high risk, whereas those below the cutoff will be classified as low risk.
11. Study endpoints The primary outcome is investigator-assessed RFS, defined as the time from surgery to the first diagnosis of recurrence or death from any cause. Event-free patients are censored at the last follow-up. Secondary outcomes included OS and recurrence patterns. OS is measured from surgery to death from any cause, with surviving patients censored at the last follow-up. Recurrence patterns are categorized by timing (early recurrence, ≤2 years after surgery; late recurrence, >2 years), location (intrahepatic, extrahepatic, or concurrent), and morphological features, including number, size, and site. Local recurrence was defined as recurrence within 2 cm of the resection margin, and distant segment recurrence as recurrence outside the adjacent hepatic segments.
12. Statistical analysis Continuous variables are presented as median (interquartile range [IQR]) and compared using the Kruskal-Wallis tests for comparisons among three groups or the Mann-Whitney U test between two groups. Categorical variables are presented as number (%) and compared usingχ2 test or Fisher's exact test. A multiple imputation approach is planned to handle possible missing data. The performance of the developed models is evaluated using the area under the ROC curve (AUC), sensitivity, specificity, positive predictive value, negative predictive value, concordance index (C-index), and calibration analysis. Interaction terms between variables that can predict MVI are analyzed using the logistics regression. The net benefits that evaluated the potential clinical utility of cfDNA signatures or MVI-prediction models are assessed by the decision curve analysis (DCA). The Delong test is used to compare differences between two ROC curves. RFS and OS are estimated using the Kaplan-Meier method and log-rank test. The univariable and multivariable Cox proportional hazards model is used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) to identify independent risk factors of RFS and OS. Variables with a p value of \<0.05 in the univariable COX analysis are selected into the multivariable analysis, and variables with a p value of \<0.05 in the multivariable COX analysis are retained in the final model. Subgroup analyses for model performances are performed based on the factors, including tumor size, hepatitis B surface antigen (HBsAg) status, and cirrhosis. A P value of \<0.05 is considered statistically significant, unless otherwise specified. Statistical analysis is performed using the python programming language version 2.7 (https://www.python.org/) and the R software version 3.1.1 (http://www.r-project.org/).
13. Reporting standards Our results will be reported per the Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) and Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) guidelines.
The criteria were revised on the registry on Sep 28, 2026. See what changed
China's National Center for Liver Cancer (NCLC)/Eastern Hepatobiliary Surgery Hospital (EHBH) maintains a prospectively collected database and biobank, which includes consecutive cases of surgically resected liver cancer between January 2015 and April 2026. We will identify study candidates from this database. A total of 3,000 eligible patients are planned to be enrolled. Their preoperative MRI data will be utilized to establish both radiomics and deep learning MVI-predictive models.
We have also established a prospective cohort of 650 patients from four Chinese tertiary medical centers: Zhongda Hospital (Southeast University), Mengchao Hepatobiliary Hospital (Fujian Medical University), Sun Yat-Sen Memorial Hospital (Sun Yat-Sen University), and Eastern Hepatobiliary Surgery Hospital (EHBH). These patients had undergone HCC resection between January 2016 and June 2019. The paired tumor/non-tumor tissue or cell-free DNA (cfDNA) sequencing data of these patients are available.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
We will develop a multimodal model to predict the preoperative risk of MVI in early-stage HCC patients. The model integrates four individual models: a clinicopathological model, an MRI-based radiomics model, an MRI-based deep learning image model, and a cfDNA genomic mutation model. The patient-level predicted probabilities of MVI from these models are calibrated into standardized MVI risk probabilities (ranging from 0.0 to 1.0) using Platt scaling or isotonic regression, and are then transformed to logits before being entered into an L2-regularized logistic stacking model. The fusion coefficients of the final multimodal system will be estimated exclusively from out-of-fold predictions. After all preprocessing, calibration, fusion and threshold-selection procedures have been locked, patients with a predicted MVI probability below the cutoff determined by the maximum Youden index (sensitivity+specificity-1) will be classified as low risk for MVI. Within this low-risk group, we assess t
Procedure: Curative-intent liver resection
We will develop a multimodal model to predict the preoperative risk of MVI in early-stage HCC patients. The model integrates four individual models: a clinicopathological model, an MRI-based radiomics model, an MRI-based deep learning image model, and a cfDNA genomic alteration model. The patient-level predicted probabilities of MVI from these models are calibrated into standardized MVI risk probabilities (ranging from 0.0 to 1.0) using Platt scaling or isotonic regression, and are then transformed to logits before being entered into an L2-regularized logistic stacking model. The fusion coefficients of the final multimodal system will be estimated exclusively from out-of-fold predictions. After all preprocessing, calibration, fusion and threshold-selection procedures have been locked, patients with a predicted MVI probability at or above the cutoff determined by the maximum Youden index (sensitivity+specificity-1) will be classified as high risk for MVI.. Within this high-risk group,
Procedure: Curative-intent liver resection
All patients have undergone curative-intent resection for early-stage HCC. A wide resection margin is defined as ≥1 cm, and a narrow margin as \<1 cm. The prognostic comparison of wide resection margin versus narrow margin will be conducted among patients who were technically eligible for either approach, as determined by clinical guidelines and the assessment of an independent panel of surgical specialists.
Recurrence-free survival (RFS)
The time from surgery to the first diagnosis of recurrence or patient death without recurrence
Time frame: Between June 2016 and April 2026
Overall survival (OS)
The time from surgery to patient death from any cause or the last follow-up
Time frame: Between June 2016 and April 2026
Local recurrence
Any recurrence located within 2 cm of the surgical resection margin
Time frame: Between June 2016 and April 2026
Ran from Jan 2022 to primary completion in Apr 2026, 51 months.
Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's 51 months is close to that.
Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jun 2022 → Apr 2026 and completion Sep 2022 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eastern Hepatobiliary Surgery Hospital